Home / Letter From The Editor / Dec. 21, 2019

Dec. 21, 2019

Dec 20, 2019

We have been following the introduction of a new oral GLP-1 analog from Novo. Although oral seems easy, the dosing schedule may be a problem that will hold up adoption.

Now there is news of an oral insulin, from Oramed Pharmaceuticals, that is moving closer to approval. Will it be a simple drug to use or will it have dosing issues? This week our publisher, Steve Freed, sits down with Oramed Pharmaceuticals’ CEO Nadav Kidron and Dr. Joel Neutel, Principal Investigator of the study, in an exclusive interview find out what the future holds and when we can expect to “swallow our insulin.”




We can make a difference!


Dave Joffe